Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Fred D Lublin, Stephen C Krieger
30 years ago the first disease-modifying therapy for relapsing multiple sclerosis was approved for use in the United States and soon thereafter across the globe. Since then the field of MS therapeutics, and studies of immunopathogenesis and genetics, have advanced our understanding of the disease and raised the hope of better addressing the next challenges of treating progressive disease, enhancing repair of the damaged nervous system and, hopefully, of a cure. Thirty years into the MS treatment era, the field continues to debate fundamental aspects of MS, and there exists a widening chasm between the triumphs in relapsing disease and the desolation of MS progression, which remains the principal unmet need...
May 26, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#2
JOURNAL ARTICLE
Maria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, Chiara Ballerini, Mario Alberto Battaglia, Roberto Bergamaschi, Giampaolo Brichetto, S Destan Bunul, Massimiliano Calabrese, Marco Capobianco, Paola Cavalla, Maria Grazia Celani, Marinella Clerico, Eleonora Cocco, Giancarlo Comi, Paolo Confalonieri, Antonella Conte, Cinzia Cordioli, Giovanna De Luca, Nicola De Rossi, Massimo Filippi, Haluk Gumes, Paolo Immovilli, Matilde Inglese, Rana Karabudak, Doriana Landi, Roberta Lanzillo, Maria Rita L'Episcopo, Lorena Lorefice, Vittorio Mantero, Sabrina Marangoni, Girolama Alessandra Marfia, Camilla Masciulli, Eva Milano, Lucia Moiola, Riccardo Orlandi, Francesco Patti, Paola Perini, Ilaria Pesci, Eugenio Pucci, Marco Puthenparampil, Marta Radaelli, Marco Salvetti, Arianna Sartori, Cinzia Scandellari, Sedat Sen, Aksel Siva, Silvia Strumia, Francesco Teatini, Gioacchino Tedeschi, Maria Trojano, Melih Tutuncu, Giovanna Vaula, Maria Pia Sormani, Maria Pia Amato
BACKGROUND: In the general population, maternal SARS-CoV-2 infection during pregnancy is associated with worse maternal outcomes; however, only one study so far has evaluated COVID-19 clinical outcomes in pregnant and postpartum women with multiple sclerosis, showing no higher risk for poor COVID-19 outcomes in these patients. OBJECTIVE: In this multicenter study, we aimed to evaluate COVID-19 clinical outcomes in pregnant patients with multiple sclerosis. METHODS: We recruited 85 pregnant patients with multiple sclerosis who contracted COVID-19 after conception and were prospectively followed-up in Italian and Turkish Centers, in the period 2020-2022...
May 26, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#3
JOURNAL ARTICLE
Nee Na Kim, Omar Abdel-Mannan, James Davidson, Pascale Du Pre, Rachel Kneen, Kshitij Mankad, Yael Hacohen
We report two children with molecularly confirmed mitochondrial disease mimicking Neuromyelitis Optica Spectrum Disorder (NMOSD). The first patient presented at the age of 15 months with acute deterioration following a pyrexial illness with clinical features localising to the brainstem and spinal cord. The second patient presented at 5 years with acute bilateral visual loss. In both cases, MOG and AQP4 antibodies were negative. Both patients died within a year of symptoms onset from respiratory failure. Arriving at an early genetic diagnosis is important for redirection of care and avoiding potentially harmful immunosuppressant therapies...
May 25, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#4
JOURNAL ARTICLE
Eoin P Flanagan, Patrick J Waters
No abstract text is available yet for this article.
May 25, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#5
JOURNAL ARTICLE
Markus Reindl, Kevin Rostasy
No abstract text is available yet for this article.
May 25, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#6
JOURNAL ARTICLE
Maciej Juryńczyk
No abstract text is available yet for this article.
May 25, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#7
JOURNAL ARTICLE
Sophie R Wilkins, Amy W Yu, Connolly Steigerwald, Kurenai Tanji, Alejandro D Iglesias, Michio Hirano, Ilya Kister, Claire S Riley, Nicolas J Abreu
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease primarily affecting the optic nerves and spinal cord, which is usually associated with anti-aquaporin-4 antibodies. Here, we present two individuals who were negative for anti-aquaporin-4 antibodies and were initially diagnosed with seronegative NMOSD. Each patient's clinical course and radiographic features raised suspicion for an alternative disease process. Both individuals were found to have pathogenic variants of MT-ND5 , encoding subunit 5 of mitochondrial complex I, ultimately leading to a revised diagnosis of a primary mitochondrial disorder...
May 25, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#8
JOURNAL ARTICLE
Matteo Gastaldi, Diego Franciotta
No abstract text is available yet for this article.
May 25, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#9
JOURNAL ARTICLE
Vyanka Redenbaugh, Nicholas H Chia, Laura Cacciaguerra, Jennifer A McCombe, Jan-Mendelt Tillema, John J Chen, A Sebastian Lopez Chiriboga, Elia Sechi, Yael Hacohen, Sean J Pittock, Eoin P Flanagan
BACKGROUND: Magnetic resonance imaging (MRI) T2-lesions resolve more often in myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) than aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and multiple sclerosis (MS) in adults but few studies analyzed children. OBJECTIVE: The main objective of this study is to investigate MRI T2-lesion evolution in pediatric MOGAD, AQP4 + NMOSD, and MS. METHODS: Inclusion criteria were as follows: (1) first clinical attack; (2) abnormal MRI (⩽6 weeks); (3) follow-up MRI beyond 6 months without relapses in that region; and (4) age < 18 years...
May 23, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#10
JOURNAL ARTICLE
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes.
Christine Lebrun-Frenay, Darin T Okuda
No abstract text is available yet for this article.
May 22, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#11
JOURNAL ARTICLE
Matilde Inglese, Maria Pia Amato
No abstract text is available yet for this article.
May 22, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#12
JOURNAL ARTICLE
Ide Smets
No abstract text is available yet for this article.
May 22, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#13
JOURNAL ARTICLE
Ebtesam Alshehri, Jeffrey A Cohen, Daniel Ontaneda, Kunio Nakamura, Scott Husak, Thomas E Love, Robert J Fox, Farren Bs Briggs, Devon S Conway
BACKGROUND: Smoking is associated with an increased risk of multiple sclerosis (MS) and disability worsening. The relationship between smoking, cognitive processing speed, and brain atrophy remains uncertain. OBJECTIVE: To quantify the impact of smoking on processing speed and brain volume in MS and to explore the longitudinal relationship between smoking and changes in processing speed. METHODS: A retrospective study of MS patients who completed the processing speed test (PST) between September 2015 and March 2020...
May 19, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#14
JOURNAL ARTICLE
Akash Virupakshaiah, Dimitrios C Ladakis, Bardia Nourbakhsh, Pavan Bhargava, Sonam Dilwali, Vinicius Schoeps, Kamil Borkowski, John W Newman, Emmanuelle Waubant
BACKGROUND: The circulating metabolome is altered in multiple sclerosis (MS), but its prognostic capabilities have not been extensively explored. Lipid metabolites might be of particular interest due to their multiple roles in the brain, as they can serve as structural components, energy sources, and bioactive molecules. Gaining a deeper understanding of the disease may be possible by examining the lipid metabolism in the periphery, which serves as the primary source of lipids for the brain...
May 18, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#15
JOURNAL ARTICLE
Thomas R Valentine, Anna L Kratz, Neeraj Kaplish, Ronald D Chervin, Tiffany J Braley
BACKGROUND: Sleep disorders are common in people with multiple sclerosis (PwMS) and could contribute to cognitive dysfunction. However, effects of pathological sleep on cognitive domains are insufficiently characterized. OBJECTIVE: To evaluate associations between cognitive performance and polysomnographic (PSG)-based sleep disturbances in PwMS. METHODS: PwMS with known/suspected untreated obstructive sleep apnea (OSA, N = 131) underwent PSG and cognitive tests: Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), California Verbal Learning Test-II (CVLT-II), Brief Visuospatial Memory Test-Revised (BVMT-R Total and Delayed), Judgment of Line Orientation (JLO), Controlled Oral Word Association Test (COWAT), Trail Making Test, Go/No-Go, and Nine-Hole Peg Test (NHPT)...
May 17, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#16
JOURNAL ARTICLE
Rocco Capuano, Luca Prosperini, Manuela Altieri, Lorena Lorefice, Roberta Fantozzi, Paola Cavalla, Clara Guaschino, Marta Radaelli, Cinzia Cordioli, Viviana Nociti, Laura Boffa, Paolo Ragonese, Maria Di Gregorio, Federica Pinardi, Valentina Torri Clerici, Giovanna De Luca, Alberto Gajofatto, Damiano Paolicelli, Carla Tortorella, Claudio Gasperini, Claudio Solaro, Eleonora Cocco, Alvino Bisecco, Antonio Gallo
BACKGROUND: Little is known about COVID-19 course and outcomes after a third booster dose of mRNA vaccine against SARS-CoV-2 (mRNA-Vax) in patients with multiple sclerosis (pwMS) treated with ocrelizumab (OCR) and fingolimod (FNG), which showed a weakened immune response to mRNA-vax. OBJECTIVES: The aim of this study was to evaluate COVID-19 course and outcomes in pwMS on OCR and FNG after receiving the third dose of mRNA-Vax and to compare it with pwMS on natalizumab (NTZ)...
May 11, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#17
JOURNAL ARTICLE
Jack A Reeves, Zachary Weinstock, Robert Zivadinov, Michael G Dwyer, Niels Bergsland, Fahad Salman, Ferdinand Schweser, Bianca Weinstock-Guttman, Ralph Hb Benedict, Dejan Jakimovski
BACKGROUND: Paramagnetic rim lesions (PRL) may be linked to relapse risk of people with relapsing-remitting multiple sclerosis (pwRRMS). OBJECTIVE: To determine the relationship between presence of PRL lesions and cognitive recovery after relapse. METHODS: PRL load was compared between acutely relapsing pwRRMS and matched stable pwRRMS controls (each group n = 21). In addition, cognitive recovery was compared between acutely relapsing pwRRMS with at least one PRL (PRL+) and those without any PRL (PRL-)...
May 9, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#18
JOURNAL ARTICLE
Shannon Kolind, Laura Gaetano, Haz-Edine Assemlal, Corrado Bernasconi, Ulrike Bonati, Colm Elliott, Niels Hagenbuch, Stefano Magon, Douglas L Arnold, Anthony Traboulsee
BACKGROUND: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by two major and interconnected hallmarks: inflammation and progressive neurodegeneration. OBJECTIVE: The aim of this work was to compare neurodegenerative processes, in the form of global and regional brain volume loss rates, in healthy controls (HCs) and in patients with relapsing MS (RMS) treated with ocrelizumab, which suppresses acute inflammation...
May 6, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#19
JOURNAL ARTICLE
Alice M Saul, Bruce V Taylor, Leigh Blizzard, Steve Simpson-Yap, Wendy H Oddy, Nittin Shivappa, James R Hébert, Lucinda J Black, Anne-Louise Ponsonby, Simon A Broadley, Jeanette Lechner-Scott, Ingrid van der Mei
BACKGROUND: A pro-inflammatory diet has been posited to induce chronic inflammation within the central nervous system (CNS), and multiple sclerosis (MS) is an inflammatory disease of the CNS. OBJECTIVE: We examined whether Dietary Inflammatory Index (DII®) ) scores are associated with measures of MS progression and inflammatory activity. METHODS: A cohort with a first clinical diagnosis of CNS demyelination was followed annually (10 years, n = 223)...
May 6, 2023: Multiple Sclerosis: Clinical and Laboratory Research
#20
JOURNAL ARTICLE
Ruth Ann Marrie
Comorbidity is highly prevalent in people with multiple sclerosis (MS) throughout their disease course. In the last 15 years, our understanding of the association between comorbidity and outcomes such as relapses, disability progressive, health-related quality of life, health care use, and mortality has grown substantially. The broad adverse impacts of comorbidity on these outcomes point to the need to prevent and treat comorbidity effectively in people with MS. This requires having the necessary tools to evaluate comorbidity, an understanding of how MS affects management of comorbidity now, testing of interventions tailored to people with MS, and determining the best models of care to optimize comorbidity management...
April 26, 2023: Multiple Sclerosis: Clinical and Laboratory Research
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
